Physician profile
Alan J Pollack
NPI 1629063052
$4,336.40
in general payments reported to CMS, 2019-2025
26 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $263 · 2021: $406 · 2022: $584 · 2023: $526 · 2024: $773 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $776.89 | 2019-2025 | Clareon, Tryptyr, Centurion |
| Sun Pharmaceutical Industries INC. | $737.26 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $564.39 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $340.82 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $279.21 | 2019-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Allergan, INC. | $198.67 | 2019-2022 | |
| Abbvie INC. | $179.10 | 2022-2024 | |
| Eyepoint US, INC. | $154.01 | 2019-2022 | |
| Biotissue Holdings INC. | $137.34 | 2025 | |
| Bausch & Lomb Americas INC. | $109.64 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $107.06 | 2019-2023 | |
| Oyster Point Pharma, INC. | $103.62 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $87.35 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $75.72 | 2024-2025 | Vevye |
| Glaukos Corporation | $70.19 | 2025 | Idosetr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65.96 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $62.35 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.04 | 2019-2021 | |
| Dompe US, INC. | $50.72 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $39.20 | 2023-2024 | Iyuzeh |
| Shire North American Group INC | $33.71 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $29.27 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $24.93 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $18.97 | 2020 | |
| Tearlab Corp | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.